Evidence map›Paper›PMID 37461686›Full record

ArticleResearch square2023

Differential Activation of Programmed Cell Death in Patients with Severe SARS-CoV-2 Infection.

Ashligh Riegler, Paul Benson, Kenneth Long, Sixto Leal

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ashligh RieglerThe University of Alabama at Birmingham.
Paul BensonThe University of Alabama at Birmingham.
Kenneth LongThe University of Alabama at Birmingham.
Sixto LealThe University of Alabama at Birmingham.
University of Alabama at Birmingham · US

Funding

Construction/SEBLAB/Regional Biocontainment LaboratoryUC6AI058599 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MARCHASE, RICHARD BANFIELD · 2003 to 2006
$22.0M
IMMUNOLOGIC DISEASES AND BASIC IMMUNOLOGYT32AI007051 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Laurie Ellen Harrington · 1985 to 2026
$13.1M
Upgrade and operational improvements to the SouthEastern Biosafety Laboratory, Alabama, Birmingham (SEBLAB)G20AI167409 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEAL, SIXTO MANUEL · 2021 to 2022
$7.7M
The Impact of SARS-CoV-2 Immune Dysregulation on Antifungal ImmunityR01AI170719 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Sixto Manuel Leal · 2023 to 2026
$2.9M
The Impact of SARS-CoV-2 Immune Dysregulation on Antifungal ImmunityR56AI170719 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEAL, SIXTO MANUEL · 2022 to 2022
$668k
NIAID NIH HHS G20 AI167409NIAID NIH HHS R01 AI170719NIAID NIH HHS R56 AI170719NIAID NIH HHS T32 AI007051NIAID NIH HHS UC6 AI058599
6 · The paper itself

Abstract

SARS-CoV-2 (SARS-2) causes severe lower airway disease and death in a subset of patients. Knowledge on the relative contribution of programmed cell death (PCD) to lung pathology is limited to few human autopsy studies with small sample size/scope, in vitro cell culture, and experimental model systems. In this study, we sought to identify, localize, and quantify activation of apoptosis, ferroptosis, pyroptosis, and necroptosis in FFPE lung tissues from patients that died from severe SARS-2 infection (n=28) relative to uninfected controls (n=13). Immunofluorescence (IF) staining, whole-slide imaging, and Image J software was used to localize and quantify expression of SARS-2 nucleoprotein and the following PCD protein markers: cleaved Caspase-3, pMLKL, cleaved Gasdermin D, and CD71, respectively. IF showed differential activation of each PCD pathway in SARS-2 infected lungs and dichotomous staining for SARS-2 nucleoprotein enabling distinction between high (n=9) vs low viral burden (n= 19). No differences were observed in apoptosis and ferroptosis in SARS-2 infected lungs relative to uninfected controls. However, both pyroptosis and necroptosis were significantly increased in SARS-2 infected lungs. Increased pyroptosis was observed in SARS-2 infected lungs, irrespective of viral burden, suggesting an inflammation-driven mechanism. In contrast, necroptosis exhibited a very strong positive correlation with viral burden (R2=0.9925), suggesting a direct SARS-2 mediated effect. These data indicate a possible novel mechanism for viral-mediated necroptosis and a potential role for both lytic programmed cell death pathways, necroptosis and pyroptosis, in mediating infection outcome.

Identifiers

PMID37461686
PMCPMC10350212
OpenAlexW4382197730

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.